Reset
Showing 20 of 25 academic articles

The immune suppressive microenvironment affects efficacy of radio‐immunotherapy in brain metastasis

Katja Niesel, Michael Schulz, Julian Anthes, Tijna Alekseeva et al. • EMBO Molecular Medicine (2021)

Abstract The tumor microenvironment in brain metastases is characterized by high myeloid cell content associated with immune suppressive and cancer‐permissive functions. Moreover, brain metastases induce the recruitment of lymphocytes. Desp...

DOAJ Open Access (DOAJ) DOI: 10.15252/emmm.202013412

A hybrid nanomodulator enables metabolic microenvironment remodeling for potent immunotherapy against lung adenocarcinoma

Shuping Wang, Pengcheng Chen, Xiaozhen Jing, Jinglin Zou et al. • Materials & Design (2026)

STING agonist-based immunotherapy holds considerable promise for cancer treatment, yet its efficacy against immunologically “cold” tumors such as lung adenocarcinoma (LUAD) remains markedly limited. A major obstacle lies in the highly glyco...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.matdes.2026.117182

Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy

Jing Ma, Ruijuan Ma, Xueke Zeng, Liming Zhang et al. • Journal of Experimental & Clinical Cancer Research (2023)

Abstract Background Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical for cancer ...

DOAJ Open Access (DOAJ) DOI: 10.1186/s13046-023-02768-0

Twins‐like nanodrugs synchronously transport in blood and coalesce inside tumors for sensitive ultrasound imaging and triggerable penetrative drug delivery

Yujun Cai, Gengjia Chen, Minzhao Lin, Bo Li et al. • Aggregate (2024)

Abstract Nanodrugs capable of aggregating in the tumor microenvironment (TME) have demonstrated great efficiency in improving the therapeutic outcome. Among various approaches, the strategy utilizing electrostatic interaction as a driving f...

DOAJ Open Access (DOAJ) DOI: 10.1002/agt2.476

In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens

Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi • BioImpacts (2019)

Introduction: Triple-negative breast cancer (TNBC) is an important subtype of breast cancer, which occurs in the absence of estrogen, progesterone and HER-2 receptors. According to the recent studies, TNBC may be a cancer testis antigen (CT...

DOAJ Open Access (DOAJ) DOI: 10.15171/bi.2019.06

Automated measurement of CD8+ T-cell distribution at the tumor epithelial–stromal interface is associated with NSCLC immunotherapy benefit and transcriptomic pathways

Patrick Leo, Hauke Kolster, Hartmut Koeppen, Jennifer Giltnane et al. • Journal of Pathology Informatics (2026)

Whereas anti-PD-(L)1 therapies are widely used in cancer treatment, only a subset of patients achieve long-term survival. Companion diagnostics based on PD-L1 expression have limited predictive power for these therapies, motivating developm...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.jpi.2026.100688

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors

Dan Lu, Yuan Chen, Min Jiang, Jie Wang et al. • Nature Communications (2023)

Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to el...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41467-023-42010-1

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer

Sophia Daum, Lilith Decristoforo, Mira Mousa, Stefan Salcher et al. • Molecular Cancer (2025)

Abstract The dynamic interactions between tumor endothelial cells (TECs) and the immune microenvironment play a critical role in the progression of non-small cell lung cancer (NSCLC). In general, endothelial cells exhibit diverse immunomodu...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12943-024-02221-6

Molecular characterization and prognostic modeling associated with M2-like tumor-associated macrophages in breast cancer: revealing the immunosuppressive role of DLG3

Ziqiang Wang, Jing Zhang, Huili Chen, Xinyu Zhang et al. • Frontiers in Immunology (2025)

BackgroundM2-like tumor-associated macrophages (TAMs) promote an immunosuppressive microenvironment and contribute to tumor progression and metastasis. However, their molecular characterization and prognostic value have not been fully explo...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2025.1650726

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology (2025)

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2024.1489827